The genomics technology producer has boosted the size of the corporate venture capital unit it announced in April last year from $100m to $189m with a $250m ceiling.
US-based genomics technology provider Illumina has increased the size of its corporate venturing unit from $100m to approximately $189m and could close it at $250m, according to a securities filing on Tuesday.
Illumina produces DNA sequencing and array-based technology for use in sectors such as life sciences, oncology, reproductive health and agriculture.
The company launched Illumina Ventures in April 2016 as an independently managed venture capital firm, pledging to invest $100m in startups over a 10-year period.
A regulatory…
